伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果及预后效果观察  

Clinical effect and prognosis of valaciclovir antiviral therapy in the treatment of recurrent genital herpes

作　　者：王莲凤 周倩 

机构地区：[1]辽阳市中心医院皮肤科,辽宁辽阳111000 [2]辽阳市中心医院妇产科,辽宁辽阳111000

出　　处：《中国性科学》2016年第9期70-72,共3页Chinese Journal of Human Sexuality

摘　　要：目的:观察伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果及预后效果。方法:从2012年8月至2014年8月我院收治的频发性生殖器疱疹中选取108例作为研究对象,按随机分组法分为A组和B组,各54例。A组采用持续抑制疗法,B组采用间歇疗法。分别于用药期间观察两组复发情况及不良反应。结果:A组在治疗期间与治疗后随访期间的复发率20.37%、48.15%,均低于B组的87.04%、92.59%;两组治疗后随访1年的复发次数均明显减少,且A组复发次数为(0.9±0.7)次,低于B组的(2.4±1.1)次。上述差异均有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹临床疗效显著,预后良好,值得临床推荐。Objectives ： To observe the effect of valaciclovir suppressive antiviral therapy in the treatment of frequent clinical effect and prognosis of recurrent genital herpes. Methods ： From August 2012 to August 2014, 108 patients with recurrent genital herpes were selected and randomly divided into group A and group B. The group A was inhibited by continuous treatment, and group B was intermittent therapy. Two groups were observed during the treatment and adverse reactions were observed. Results： The recurrence rate of group A during and after treatment was 20. 37% and 48.15% , which was lower than that of B group of 92.59% and 87.04%. In the 1 year follow - up, the number of recurrence of group A was （0.9 ± 0.7 ）, lower than the group B （2.4±1.1 ）. The difference was statistically significant （ P 〈 0. 05 ）. Difference in the incidence of adverse reactions in the two groups was not statistically significant （ P 〉 0. 05 ）. Conclusion ： Valacyelovir antiviral suppression therapy in the treatment of frequent sexual genital bleb has a significant clinical efficacy with good prognosis, worthy of clinical recommendations.

关 键 词：伐昔洛韦 病毒抑制疗法 频发性生殖器疱疹 效果 

分 类 号：R752.1[医药卫生—皮肤病学与性病学]